Patents by Inventor Jason Wu

Jason Wu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12291530
    Abstract: The present disclosure describes GLP-1R modulating compounds that are useful for treating GLP-1R-mediated diseases or conditions.
    Type: Grant
    Filed: September 13, 2024
    Date of Patent: May 6, 2025
    Assignee: Ascletis Pharma (China) Co., Limited
    Inventors: Bin Liang, Jinzi Jason Wu, Bailing Yang
  • Publication number: 20250129058
    Abstract: The present disclosure describes a PTPN2/PTP1B degrader compounds having the structure of Formula (I), that are useful for treating PTPN2/PTP1B-mediated disorders or conditions,
    Type: Application
    Filed: October 17, 2024
    Publication date: April 24, 2025
    Inventors: Lei Han, Jinzi Jason Wu
  • Patent number: 12234236
    Abstract: The present disclosure describes GLP-1R modulating compounds that are useful for treating GLP-1R-mediated diseases or conditions,
    Type: Grant
    Filed: September 13, 2024
    Date of Patent: February 25, 2025
    Assignee: Ascletis Pharma (China) Co., Limited
    Inventors: Bin Liang, Jinzi Jason Wu, Bailing Yang
  • Publication number: 20250054451
    Abstract: In some examples, a display device includes a panel, a scaler circuit, and a backlight control circuit. In some examples, the scaler circuit receives a panel identification from the panel and determines a backlight module driving configuration based on the panel identification. In some examples, the backlight control circuit receives the backlight module driving configuration from the scaler circuit and controls a backlight for the panel based on the backlight module driving configuration.
    Type: Application
    Filed: December 17, 2021
    Publication date: February 13, 2025
    Applicant: Hewlett-Packard Development Company, L.P.
    Inventors: Chih-Ping Tom Chung, Yi-Fan Lin, Jung-Fang Jason Wu
  • Publication number: 20250029626
    Abstract: The disclosed technology relates to methods, voice enhancement systems, and non- transitory computer readable media for real-time voice enhancement. In some examples, input audio data including foreground speech content, non-content elements, and speech characteristics is fragmented into input speech frames. The input speech frames are converted to low-dimensional representations of the input speech frames. One or more of the fragmentation or the conversion is based on an application of a first trained neural network to the input audio data. The low-dimensional representations of the input speech frames omit one or more of the non-content elements. A second trained neural network is applied to the low-dimensional representations of the input speech frames to generate target speech frames. The target speech frames are combined to generate output audio data. The output audio data further includes one or more portions of the foreground speech content and one or more of the speech characteristics.
    Type: Application
    Filed: October 4, 2024
    Publication date: January 23, 2025
    Inventors: Shawn ZHANG, Lukas PFEIFENBERGER, Jason WU, Piotr DURA, David BRAUDE, Bajibabu BOLLEPALLI, Alvaro ESCUDERO, Gokce KESKIN, Ankita JHA, Maxim SEREBRYAKOV
  • Publication number: 20250009726
    Abstract: A pharmaceutical composition comprises, in weight parts, the following components: (a) 1 part compound as shown in formula (I) (b) 0.2 to 15 parts polyvinylpyrrolidone; and (c) 1 part to 25 parts other pharmaceutically acceptable excipients. This pharmaceutical composition can be used for the treatment of steatohepatitis.
    Type: Application
    Filed: September 9, 2021
    Publication date: January 9, 2025
    Inventors: Kunhua DONG, Jinzi Jason WU
  • Publication number: 20250011303
    Abstract: The present application describes compounds of IL-17A modulator that are useful for treating an IL-17A mediated inflammatory syndrome, disorder, or disease.
    Type: Application
    Filed: May 17, 2024
    Publication date: January 9, 2025
    Inventors: Bin Liang, Bailing Yang, Donghuang Liu, Jinzi Jason Wu
  • Patent number: 12187704
    Abstract: Certain antiviral compounds, pharmaceutical compositions, and methods related thereto are disclosed.
    Type: Grant
    Filed: May 30, 2023
    Date of Patent: January 7, 2025
    Assignee: Ascletis BioScience Co., Ltd.
    Inventor: Jinzi Jason Wu
  • Publication number: 20240428068
    Abstract: In view of the need for a conversational recommender system (CRS) in guiding purchasing processes of complex items, embodiments described herein provide a CRS system that creates a realistic purchase scenario and agent evaluation for fulfilling the recommendation objective. Specifically, the CRS system utilizes existing buying guides as a knowledge source for the recommendation model.
    Type: Application
    Filed: December 21, 2023
    Publication date: December 26, 2024
    Inventors: Lidiya Murakhovs'ka, Philippe Laban, Tian Xie, Chien-Sheng (Jason) Wu
  • Publication number: 20240411992
    Abstract: Embodiments described herein provide a training framework for generative NLP models. Specifically, the training input, e.g., in the form of a sequence of tokens representing a user-agent dialogue, may be randomly masked for a few spans, which can be one or more tokens, one or more words, one or more sentences, or one or more paragraphs. These masked spans are replaced with their embeddings generated from pre-trained large language models are then used for training the NLP model.
    Type: Application
    Filed: June 15, 2023
    Publication date: December 12, 2024
    Inventors: Shiva Kumar Pentyala, Prafulla Kumar Choubey, Shashank Harinath, Sitaram Asur, Chien-Sheng Jason Wu, Zachary Alexander, Caiming Xiong
  • Publication number: 20240411991
    Abstract: Embodiments described herein provide a training framework for generative NLP models that operate on previously learnt knowledge from pretrained large language models. Specifically, to train an NLP model to generate a response to a user utterance (e.g., “resolve login issue”), document embeddings of support IT documents encoded by a pretrained LLM are fed to an NLP decoder together with a training dialogue (e.g., a dialogue between the chat agent on how to “resolve login issue”). The NLP decoder can thus be trained by a causal language modeling loss computed based on the predicted next token and the ground-truth token from the training dialogue.
    Type: Application
    Filed: June 6, 2023
    Publication date: December 12, 2024
    Inventors: Shiva Kumar Pentyala, Prafulla Kumar Choubey, Shashank Harinath, Sitaram Asur, Chien-Sheng Jason Wu, Zachary Alexander, Caiming Xiong
  • Patent number: 12125496
    Abstract: The disclosed technology relates to methods, voice enhancement systems, and non-transitory computer readable media for real-time voice enhancement. In some examples, input audio data including foreground speech content, non-content elements, and speech characteristics is fragmented into input speech frames. The input speech frames are converted to low-dimensional representations of the input speech frames. One or more of the fragmentation or the conversion is based on an application of a first trained neural network to the input audio data. The low-dimensional representations of the input speech frames omit one or more of the non-content elements. A second trained neural network is applied to the low-dimensional representations of the input speech frames to generate target speech frames. The target speech frames are combined to generate output audio data. The output audio data further includes one or more portions of the foreground speech content and one or more of the speech characteristics.
    Type: Grant
    Filed: April 24, 2024
    Date of Patent: October 22, 2024
    Assignee: SANAS.AI INC.
    Inventors: Shawn Zhang, Lukas Pfeifenberger, Jason Wu, Piotr Dura, David Braude, Bajibabu Bollepalli, Alvaro Escudero, Gokce Keskin, Ankita Jha, Maxim Serebryakov
  • Patent number: 12116922
    Abstract: A catalytic converter system having oxygen storage materials is disclosed and methods for determining whether to reactivate oxygen storage materials and monitoring failure events of the oxygen storage materials are also disclosed.
    Type: Grant
    Filed: April 17, 2023
    Date of Patent: October 15, 2024
    Assignee: Ford Global Technologies, LLC
    Inventors: Jason Wu, Eva Thanasiu, Giovanni Cavataio, Carolyn Parks Hubbard, Andrew Gregory Getsoian, Yisun Cheng, Natalie Roxas, Michael James Uhrich
  • Publication number: 20240325417
    Abstract: A pharmaceutical composition comprising: a compound of formula (I) formulated for storage at room temperature and at least one additional therapeutic agent.
    Type: Application
    Filed: July 5, 2022
    Publication date: October 3, 2024
    Inventor: Jinzi Jason WU
  • Publication number: 20240327428
    Abstract: The present application describes compounds of capsid inhibitors that are useful for treating HIV infection in a human. One aspect of the present application relates to a compound of Formula I, stereoisomers thereof, pharmaceutically acceptable salts thereof, or deuterium substitutes thereof as described in the present disclosure.
    Type: Application
    Filed: February 22, 2024
    Publication date: October 3, 2024
    Inventors: Jinzi Jason WU, Bin LIANG, Bailing YANG
  • Patent number: 12084469
    Abstract: A method for preparing the cyclic phosphonate compound of Formula I is described. The method significantly improves the stereoselectivity of the compound with the required configuration.
    Type: Grant
    Filed: June 27, 2023
    Date of Patent: September 10, 2024
    Assignee: GANNEX PHARMA CO., LTD.
    Inventors: Jinzi Jason Wu, Bailing Yang, Bin Liang
  • Publication number: 20240294561
    Abstract: The present application describes a thyroid hormone receptor ? subtype agonist derivative, a preparation method and a use thereof.
    Type: Application
    Filed: February 6, 2024
    Publication date: September 5, 2024
    Inventors: Jinzi Jason Wu, Bin Liang
  • Publication number: 20240293385
    Abstract: A pharmaceutical composition comprising: a form of compound of formula (I) and at least one additional therapeutic agent, and optionally one or more pharmaceutically acceptable carriers.
    Type: Application
    Filed: July 5, 2022
    Publication date: September 5, 2024
    Inventor: Jinzi Jason WU
  • Publication number: 20240270756
    Abstract: Disclosed are a compound of Formula I, stereoisomers, pharmaceutically acceptable salts and deuterated compounds thereof and a method for treating, inhibiting and/or preventing a disease or disorder in a subject in need thereof: wherein A, R, G, Y and n are defined as in the present disclosure.
    Type: Application
    Filed: January 18, 2024
    Publication date: August 15, 2024
    Inventors: Jinzi Jason WU, Bin LIANG
  • Publication number: 20240207290
    Abstract: A pharmaceutical composition comprising: a compound of formula (1) and a polymer material, wherein the compound of formula (1) maintains a supersaturated concentration in the pharmaceutical composition and is suitable for storage at room temperature.
    Type: Application
    Filed: March 18, 2022
    Publication date: June 27, 2024
    Inventors: Xuyu Chai, Jinzi Jason Wu